- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00805402
Interest of Flow Cytometry for the Diagnosis, the Follow up and Specific Immunotherapy (SIT) Arrest of Hymenoptera Venom Allergy (Cytoven)
Interest of Flow Cytometry for the Diagnosis, the Follow up and SIT Arrest of Hymenoptera Venom Allergy
The aim of this study is to show that flow cytometry can be an accurate tool to help physicians regarding the diagnosis, the SIT decision and the SIT arrest of hymenoptera venom allergy.
75 patients having a story of reaction to hymenoptera venom will be selected for this trial.
Blood samples will be analyzed at: inclusion visit, Week 1 visit, Week 3 visit, Week 10 and Week 21 visit.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Limoges, France, 87000
- Service Pathologie Respiratoire
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult patient (18 - 70 years)
- Patient being informed and accepting to participate in the study with signature of informed consent
- Patients having a clinical systematic and local, loco-regional story of reaction to the piqures of hymenopterans.
- Patients treated by SIT for at least 5 years
- Patients benefiting from a national insurance health
Exclusion Criteria:
- Children
- Pregnant woman or who breast-feed
- Patient under antihistaminic or corticoid for less than 8 days before the blood drawing
- Protected Patient
- Patient not having given his agreement after it was informed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1 flow cytometry
flow cytometry
|
flow cytometry
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
% CD63 expression on basophil membrane by flow Cytometry
Time Frame: Inclusion , Week 1, Week 3, Week 10 and Week 21 visits
|
Inclusion , Week 1, Week 3, Week 10 and Week 21 visits
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Blood blocking factors level
Time Frame: Week 1, Week 3, Week 10 and Week 21 visits
|
Week 1, Week 3, Week 10 and Week 21 visits
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michel COGNE, MD, CHU Limoges
- Study Chair: Jean Sainte-Laudy, PhD, CHU Limoges
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- I07021
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.